Source: Biomedicine & Pharmacotherapy. Unidades: FM, ICB
Subjects: FISIOLOGIA, FÁRMACOS (SISTEMA NERVOSO CENTRAL), ANTIDEPRESSIVOS, RECEPTORES DE SEROTONINA, LIPÍDEOS, FRUTOSE, MELATONINA, HIPERTRIGLICERIDEMIA, FÍGADO GORDUROSO, RATOS WISTAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VERONESI, Vanessa Barbosa et al. Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats. Biomedicine & Pharmacotherapy, v. 141, p. 1-12, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.biopha.2021.111807. Acesso em: 16 nov. 2024.APA
Veronesi, V. B., Pioli, M. R., Souza, D. N. de, Teixeira, C. J., Murata, G. M., Silva, J. C. S., et al. (2021). Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats. Biomedicine & Pharmacotherapy, 141, 1-12. doi:10.1016/j.biopha.2021.111807NLM
Veronesi VB, Pioli MR, Souza DN de, Teixeira CJ, Murata GM, Silva JCS, Hecht FB, Vicente JM, Bordin S, Anhê GF. Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats [Internet]. Biomedicine & Pharmacotherapy. 2021 ; 141 1-12.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2021.111807Vancouver
Veronesi VB, Pioli MR, Souza DN de, Teixeira CJ, Murata GM, Silva JCS, Hecht FB, Vicente JM, Bordin S, Anhê GF. Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats [Internet]. Biomedicine & Pharmacotherapy. 2021 ; 141 1-12.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2021.111807